AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Somatostatin receptor type 2

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

This includes comprehensive molecular simulations of the receptor in its native membrane environment, paired with ensemble virtual screening that factors in its conformational mobility. In cases involving dimeric or oligomeric receptors, the entire functional complex is modelled, pinpointing potential binding pockets on and between the subunits to capture the full range of mechanisms of action.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

P30874

UPID:

SSR2_HUMAN

Alternative names:

SRIF-1

Alternative UPACC:

P30874; A8K3Y0; B2R9P7; Q4VBP0; Q96GE0; Q96TF2; Q9BWH1

Background:

Somatostatin receptor type 2 (SSTR2), also known as SRIF-1, plays a pivotal role in mediating the effects of somatostatin-14 and -28. It is involved in a wide range of cellular processes, including inhibition of adenylyl cyclase, stimulation of phosphotyrosine phosphatase and PLC, and suppression of voltage-dependent calcium channels. SSTR2's influence extends to the regulation of hormone secretion in pancreatic cells, cell growth modulation, and neuronal development.

Therapeutic significance:

Understanding the role of Somatostatin receptor type 2 could open doors to potential therapeutic strategies. Its involvement in critical cellular processes and hormone regulation positions it as a key target for drug discovery efforts aimed at treating metabolic disorders, growth abnormalities, and neurodevelopmental conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.